Abstract
Purpose
The usefulness of 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy in predicting the effectiveness of β-blocker therapy in dilated cardiomyopathy (DCM) was investigated from the standpoint of long-term prognosis.
Methods
The subjects were 53 DCM patients in whom β-blockers had been successfully introduced and used for 6 months or longer. When symptoms were stable before the introduction of β-blockers and for up to 1 year thereafter, MIBG myocardial single-photon emission computed tomography was performed and the images analysed to obtain the extent score (EXT), severity score (SEV) and washout rate (WR). At the same time, echocardiography was performed to measure left ventricular ejection fraction (LVEF). Thereafter, patients were placed under observation for an average of 1,314±986 days, with the occurrence of cardiac events as the endpoint.
Results
The degree of improvement in WR after introduction of β-blockers was a significant predictor of cardiac events. In fact, none of the patients whose improvement in WR was valued at 10 or higher had cardiac events. Accordingly, using improvement in WR of 10 as the cut-off value, the patients were divided into two groups, “improved” and “unimproved”. There were significant differences between the groups in respect of early EXT, early SEV and WR before the introduction of β-blockers . As regards predictors of WR improvement, multivariate logistic regression analysis demonstrated that early EXT, WR and LVEF were significant predictors.
Conclusion
This study shows that, from the standpoint of long-term prognosis, DCM patients who would benefit the most from β-blocker therapy are those with low early EXT and early SEV and high WR before β-blocker introduction regardless of LVEF values.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Packer M, Bristow M-R, Cohn J-N, Colucci W-S, Fowler M-B, Gilbert E-M, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 1996;334:1349–55
Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001–7
The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999;353:9–13
Wieland D-M, Brown LE, Rogers W-L, Worthington K-C, Wu J-L, Clinthorne N-H, Otto C-A, Swanson D-P, Beierwaltes W-H. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981;22:22–31
Sisson J-C, Shapiro B, Meyers L, Mallette S, Mangner T-J, Wielamd D-M, Glowniak J-V, Sherman P, Beierwaltes W-H. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987;28:1625–36
Suwa M, Otake Y, Moriguchi A, Ito T, Hirota Y, Kawamura K, Adachi I, Narabayashi I. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to β-blocker therapy in patients with dilated cardiomyopathy. Am Heart J 1997;133:353–8
Kakuchi H, Sasaki T, Ishida Y, Komamura K, Miyatake K. Clinical usefulness of 123I-meta-iodobenzylguanidine imaging in predicting the effectiveness of β blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment. Heart 1999;81:148–52
Yamazaki J, Muto H, Kabano T, Yamashina S, Nanjo S, Inoue A. Evaluation of β-blocker therapy in patients with dilated cardiomyopathy—clinical meaning of iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J 2001;141:645–52
McDermott MM, Feinglass J, Lee PI, Mehta S, Schmitt B, Lefevre F, Gheorghiade M. Systolic function, readmission rates, and survival among consecutively hospitalized patients with congestive heart failure. Am Heart J 1997;134:728–36
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, Dibianco R, Zeldis SM, Hendrix GH, Bammer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shanon J, Tandon PK, Demets DL, for the PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468–75
Goldman S, Johnson G, Cohn JN, Cintron G, Smith R, Francis G, for the V-HEFT VA cooperative studies group. Mechanism of death in heart failure. The Vasodilator-Heart Failure Trials. Circulation 1993;87(Suppl VI):24–31
Cohn JN, Jihnson GR, Kay HR. Clinical determinations of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Circulation 1993;87(Suppl IV):15–16
Merlet P, Pouillart F, Dubois-Rande JL, Delahaye N, Fumey R, Castaigne A, Syrota A. Sympathetic nerve alterations assessed with 123I-MIBG in the falling human heart. J Nucl Med 1999;40:224–31
Toyama T, Aihara Y, Iwasaki T, Hasegawa A, Suzuki T, Nagai R, Endo K, Hoshizaki H, Oshima S, Taniguchi K. Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after β-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med 1999;40:217–23
Agostini D, Belin A, Amar MH, Darlas Y, Hamon M, Grollier G, Potier JC, Bouvard G. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphy study. J Nucl Med 2000;41:845–51
Lotze U, Kaepplinger S, Kober A, Richartz BM, Gottschild D, Figulla HR. Recovery of the cardiac adrenergic nervous system after long-term β-blocker therapy in idiopathic dilated cardiomyopathy: assessment by increase in myocardial 123I-metaiodobenzylguanidine uptake. J Nucl Med 2001;42:49–54
Yamada T, Fukunami M, Ohmori M, Iwakura K, Kumagai K, Kondoh N, Tsujimura E, Abe Y, Nagareda T, Kotoh K. Which subgroup of patients with dilated cardiomyopathy would benefit from long-term beta-blocker therapy? A histologic viewpoint. J Am Coll Cardiol 1993;21:628–33
Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, Tsuchihashi K, Shimamoto K. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by metaiodobenzylguanidine in patients with failing and non-failing hearts. J Nucl Cardiol 1998;5:579–90
Kakuchi H, Sasaki T, Ishida Y, Komamura K, Miyatake K. Clinical usefulness of 123I-meta-iodobenzylguanidine imaging in predicting the effectiveness of β blockers for patients with idiopathic DCM before and soon after treatment. Heart 1999;81:148–52
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fujimoto, S., Inoue, A., Hisatake, S. et al. Usefulness of 123I-metaiodobenzylguanidine myocardial scintigraphy for predicting the effectiveness of β-blockers in patients with dilated cardiomyopathy from the standpoint of long-term prognosis. Eur J Nucl Med Mol Imaging 31, 1356–1361 (2004). https://doi.org/10.1007/s00259-004-1557-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-004-1557-2